ProtoKinetix Inc (PKTX)

[PK holder]

Another stock that has recently gotten my attention is ProtoKinetix, OTCQB:PKTX. At the core of ProtoKinetix's is an anti-aging glycopeptide, trademarked AAGP™. Basically, AAGP is a molecule that promotes cell therapy. The stock got my attention because it showed up on a recent stock screening search for insider buying. The other thing that got my attention was the stock has been trading 2x daily trading volume the last few weeks. The combination of insider buying and increased volume was worth a deeper look.
In reviewing recent press releases, in April, the company outlined the steps needed for clinical trial. In May they had press giving an update of progress towards clinical trial. They have also been working with the University of Alberta the last few years and the studies have been on the use of AAGP for organ transplants, rheumatoid arthritis, multiple sclerosis and Type 1 diabetes. So, this appears to be a company headed to clinical trials in the next 12 months. Stock is currently trading at .07 and a modest market cap of $16 million, it looks like a good time to begin accumulating.